Lung nodule

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Retrieved on: 
Wednesday, May 24, 2023
Oncology, Health, Health Technology, Genetics, Other Health, Clinical Trials, Biotechnology, CT, Lung nodule, University, HRCT, ATS, University of Washington Medical Center, UIP, Cancer, Lung cancer, ILD, FVC, American Thoracic Society, Interstitial lung disease, Restrictive lung disease, Vital capacity, Patient, Physician, Risk, Vicki Belo, Diagnosis, IPF, Massachusetts General Hospital, Idiopathic pulmonary fibrosis, Medical device, Pharmaceutical industry, Medical imaging

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer.
  • The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C.
  • For Veracyte’s Percepta Nasal Swab, researchers presented updated preliminary study findings showing the test’s potential to better stratify the risk of lung cancer for patients with lung nodules.
  • “Importantly, these findings suggest that our tests in interstitial lung disease and lung cancer are performing as intended.”

AtlantiCare First in Northeast to Deploy Optellum AI Alongside Robotics for Early Lung Cancer Diagnosis and Treatment

Retrieved on: 
Thursday, February 23, 2023
ARMC, Johnson & Johnson, Doctor of Philosophy, Cancer, Diagnosis, EGG, Lung nodule, NYSE, Disease, AtlantiCare, Partnership, Interventional pulmonology, Risk, Survival rate, FDA, Oncology, Patient, CT, Lung cancer, American Lung Association, Heart & Lung, JNJ, Biopsy, Neoplasm, AtlantiCare Regional Medical Center, Mainland Campus, UKCA, Physician, Medical imaging, Medical device, Ethicon, EU

EGG HARBOR TOWNSHIP, N.J., Feb. 23, 2023 /PRNewswire/ -- AtlantiCare is the first healthcare system in the northeastern U.S. to use Optellum's Virtual Nodule Clinic. Located in New Jersey, it is integrating the innovative technology into its early lung cancer diagnosis program at its Heart & Lung and Cancer Care institutes at AtlantiCare Regional Medical Center (ARMC).

Key Points: 
  • Located in New Jersey, it is integrating the innovative technology into its early lung cancer diagnosis program at its Heart & Lung and Cancer Care institutes at AtlantiCare Regional Medical Center (ARMC).
  • Lung cancer is among the most common types of cancer and the leading cause of cancer deaths in the world, according to the American Lung Association .
  • Optellum's integrated Lung Cancer Prediction capability also helps AtlantiCare clinicians prioritize patients at high risk of having lung cancer.
  • "We have already identified suspicious tumors in individuals who have no known risk of lung cancer through this technology," added Borah.

With 5.41% CAGR, Molecular Imaging Market Size to Hit USD 7.3 Billion by 2032 | Future Market Insights

Retrieved on: 
Wednesday, September 14, 2022
Photon, Siemens, Single-photon emission computed tomography, Conditional sentence, Siemens Healthineers, Adoption, Health, Cardiology, Time, Molecular imaging, Gynaecology, Hospital, Philips, Prevalence, Functional neurologic disorder, Acquisition, Growth, Biotelemetry, Isotopia Festival, Industry, Deep learning, Canon Medical Systems Corporation, Lung cancer, PET, Degenerative disease, Cancer, Lung nodule, Bruker, Technology, FMI, Lists of diseases, Market, CT, Diagnosis, SPECT, Health care, Awareness, Lists of countries and territories, Globe, Radiology, Positron emission tomography, CAGR, Agriculture, Medical imaging, Fine chemical, Renewable energy, Software

NEWARK, Del., Sept. 14, 2022 /PRNewswire/ -- The global molecular imaging market is anticipated to value at US$ 7.3 Billion while expanding at a CAGR of 5.41% during the forecast period of 2022-2032. The growth of the market can be attributed to the increasing incidences of chronic illness across the globe.

Key Points: 
  • Growing Adoption of AI-Based Technology in the Healthcare Sector to Expand the Molecular Imaging Market at a CAGR of 5.41% by 2032.
  • In Europe, the molecular imaging market is expected to display a CAGR of 4% during the forecast period.
  • Key Takeaways from the Market Study:
    The global molecular imaging market is expected to secure US$ 4.309 Billion in 2022.
  • Future Market Insights,in its new offering, presents an unbiased analysis of the global molecular imaging market, presenting a historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

Retrieved on: 
Wednesday, July 13, 2022
Research, Medical Devices, Genetics, Clinical Trials, Health Technology, Biotechnology, Health, Science, Oncology, Regulation of tobacco by the U.S. Food and Drug Administration, SEC, Physician, Malignancy, Incidence, Annual report, Skin, AEGIS, Form 10-Q, Lung nodule, GSC, Risk, Patient, ROM, Bronchoscopy, Food, PPV, Â, Investor, Diagnosis, LDT, NPV, Laboratory, Cancer, Machine learning, Medicare, Health, Forward-looking statement, Smoker, RNA, FDA, Twitter, Lung cancer, PLOS, Medical imaging, Medical device, TTEC

(Nasdaq: VCYT) announced that new data published today in PLOS ONE show that the companys Percepta Genomic Sequencing Classifier (GSC) is highly accurate in re-classifying lung cancer risk among patients with lung nodules whose bronchoscopy results are inconclusive.

Key Points: 
  • (Nasdaq: VCYT) announced that new data published today in PLOS ONE show that the companys Percepta Genomic Sequencing Classifier (GSC) is highly accurate in re-classifying lung cancer risk among patients with lung nodules whose bronchoscopy results are inconclusive.
  • The findings from this study suggest that the Percepta GSC provides accurate, objective information that can help resolve this challenge.
  • Across all pre-bronchoscopy risk groups, the Percepta GSC re-classified nearly 40% (39.1%) of patients into a different category of cancer risk.
  • The Percepta GSC stratifies the risk of primary lung cancer across all pre-bronchoscopy risk groups to guide patient management when bronchoscopy is inconclusive.

Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medicine, Lung cancer, Medical tests, Clinical medicine, Health, Radiology, Lung nodule, Screening, Cancer screening, Cancer, CT scan, Oncology

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.
  • The Median Technologies iBiopsy Lung Cancer Development Plan was launched in February 2021 , as part of the Companys strategic positioning in early-stage disease diagnosis.
  • Major international studies have shown that LDCT lung cancer screening can reduce mortality by 44% (NELSON Trial, 2018).
  • The study was based on a cohort of 1,696 patients from the National Lung Screening Trial cases (NLST) consisting of a total of 15,608 lung nodules.

Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection

Retrieved on: 
Wednesday, May 19, 2021
Oncology, Health, Genetics, General Health, Radiology, Pharmaceutical, Biotechnology, Lung cancer, Lung nodule, CT scan, Positive and negative predictive values, Medicine, Clinical medicine, Health, Lung Cancer, Veracyte, LUNG CANCER, VERACYTE

(Nasdaq: VCYT) today announced pivotal clinical validation data showing that the company\xe2\x80\x99s noninvasive nasal swab test can significantly improve the early assessment of lung cancer.

Key Points: 
  • (Nasdaq: VCYT) today announced pivotal clinical validation data showing that the company\xe2\x80\x99s noninvasive nasal swab test can significantly improve the early assessment of lung cancer.
  • \xe2\x80\x9cToday, physicians have limited objective tools to determine which patients with lung nodules found on CT scans have cancer and which don\xe2\x80\x99t.
  • Our findings showed that the nasal swab test can determine, with a high level of accuracy, which patients are at low risk of cancer and can avoid invasive procedures.
  • Similarly, the positive predictive value (PPV) is 67%, meaning that nearly 70% of patients classified as high risk will have lung cancer.

Biodesix Announces Presentation on Use of Biomarker-Based Risk Assessment to Inform Lung Nodule Management

Retrieved on: 
Thursday, April 22, 2021
Medical Supplies, Health, Infectious diseases, Other Health, General Health, Biotechnology, Biology, Branches of biology, Biomarkers, Life sciences, Lung cancer, Lung nodule

b'Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a webinar to discuss biomarkers and risk assessment in lung nodule management.

Key Points: 
  • b'Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a webinar to discuss biomarkers and risk assessment in lung nodule management.
  • \xe2\x80\x9cMost lung nodules are benign, so it can be challenging to determine which patients should be evaluated for a diagnostic procedure.
  • Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung.
  • Biodesix also collaborates with many of the world\xe2\x80\x99s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

Teleradiology Leader Receives FDA Clearance for Its Lung Nodule Measurement Tool Built with Artificial Intelligence

Retrieved on: 
Tuesday, March 30, 2021
Medicine, Radiology, Medical specialties, Health care, Medical imaging, Image processing, Telemedicine, Teleradiology, Lung nodule, Food and Drug Administration, Nodule

PALO ALTO, Calif., March 30, 2021 /PRNewswire/ -- Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative lung nodule measurement tool built with artificial intelligence (AI) that can accelerate diagnoses of certain respiratory diseases.

Key Points: 
  • PALO ALTO, Calif., March 30, 2021 /PRNewswire/ -- Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative lung nodule measurement tool built with artificial intelligence (AI) that can accelerate diagnoses of certain respiratory diseases.
  • The FDA clearance for NinesMeasure is the second FDA clearance in 10 months for the Silicon Valley based teleradiology practice, demonstrating the company's commitment to transforming the use of technology in radiology.
  • Last April, Nines also received FDA clearance for artificial intelligence technology that triages mass effect conditions and intracranial hemorrhages.
  • Lung nodule measurement can be tedious and time consuming as each nodule has to be measured carefully to determine changes in size over time.

Veracyte Commends New USPSTF Lung Cancer Screening Guidelines

Retrieved on: 
Wednesday, March 10, 2021
Biotechnology, Genetics, Health, Oncology, Lung cancer, Medicine, Cancer screening, Health, Clinical medicine, Health effects of tobacco, United States Preventive Services Task Force, Cancer, Screening, Thyroid cancer, Breast cancer, Lung nodule, Lung Cancer, Veracyte

(Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening.

Key Points: 
  • (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening.
  • We commend the USPSTF for their new lung cancer screening recommendations, which will help ensure that more lives are saved through early detection, said Bonnie Anderson, Veracytes chairman and chief executive officer.
  • Much work remains in the fight against lung cancer, including ensuring that physicians have optimal tools to help guide patient care when potentially cancerous lung nodules are found through screening.
  • The companys tests in lung cancer, breast cancer, thyroid cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development.

Biodesix Initiates Biomarker Study to Affirm Nodify XL2® Test’s Importance in Clinical Decision Making

Retrieved on: 
Wednesday, December 23, 2020
Biotechnology, Health, Clinical trials, Medical Supplies, Oncology, Lung cancer, Clinical research, Design of experiments, Lung nodule, Randomized controlled trial, Methodology, Research, Knowledge, Veristrat

The Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules (ALTITUDE), titled A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Test in Incidentally Discovered Low to Moderate Risk Lung Nodules , is a randomized blinded controlled study with the objective of assessing how clinical decision making is impacted by the introduction of Nodify Lung test results into risk assessment.

Key Points: 
  • The Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules (ALTITUDE), titled A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Test in Incidentally Discovered Low to Moderate Risk Lung Nodules , is a randomized blinded controlled study with the objective of assessing how clinical decision making is impacted by the introduction of Nodify Lung test results into risk assessment.
  • Biodesix has selected Dr. Gerard Silvestri, Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina, to lead this trial.
  • We expect the trial to demonstrate that having the results of the Nodify XL2 Lung tests will lead to patients with benign disease avoiding unnecessary and invasive procedures.
  • As a data-driven company, Biodesix is committed to continuing to study our tests and their impact on patients and the healthcare system.